Please login to the form below

Not currently logged in
Email:
Password:

Calchan names Zahid Ali as chief scientific officer

Ali joins from Pfizer where he was a senior director

edit-calchan-zahid-aliUK-based biotech company Clachan has appointed Zahid Ali as chief scientific officer.

Calchan works with a focus on research and development of novel molecules targeting pain and imflammation, complementing Ali's two decades of industry experience and extensive knowledge of the area.

Commenting on his appointment, Ali said: “I am very excited to be joining Calchan, which has a management team of enviable experience and a very successful track record in the sector. 

“I believe the company's products have significant potential and I am looking forward to working with the team to secure Calchan's position as a leader in this field.”

Ali joins from Pfizer, where he held the position of senior director of clinical research and was responsible for a number of early clinical development programmes focused on pain research.

He began his career at Merck Sharp and Dohme Research Laboratories UK before increasing his seniority at companies including GSK, where he worked as director of discovery medicine.

Brenda Reynolds, CEO at Calchan, added: “Zahid Ali's appointment is an important one as we continue to assemble a strong team to develop our assets at Calchan. I am delighted that Zahid has chosen to join us as his considerable experience and background, notably as a Clinical Director at Pfizer, will be invaluable.”

15th May 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...

Infographics